KANSAS CITY, Mo., Sept. 29 /PRNewswire/ — In recognition of Hispanic Heritage Month, Teva Neuroscience, Inc., marketers of the once-daily Parkinson’s disease (PD) drug AZILECT (R) (rasagiline tablets), today announced the launch of the Spanish version of their patient and caregiver resource Web site, http://azilect.com/espanol . The Spanish Web site was created to provide important information and resources to members of the Hispanic community, living in the U.S., who are affected by PD, an age-related degenerative disorder of the brain.
“Unfortunately, there are not a lot of resources for Spanish-speaking patients dealing with Parkinson’s disease,” said Dr. Ramon L. Rodriguez, director of clinical services at the University of Florida’s Movement Disorders Center. “Even though there is no cure for Parkinson’s, it is important for patients to learn how to live well through a combination of activities and treatments that can help control the symptoms of the disease.”
The Spanish Web site, http://azilect.com/espanol , is a comprehensive resource that provides important information to help patients and families with the physical and emotional effects of PD. Spanish-speaking visitors will be able to access a wide range of information and resources, including:
— Basic disease information and treatment options
— Signs and symptoms of the disease
— Tips on living well through a combination of treatment, activities, and support
— Downloadable worksheets and links to various other resources
— Caregiver information
Additionally, visitors will have access to a downloadable version of the recently released “Hacia adelante” resource guide. The easy-to-use guide is a useful tool that helps people affected by PD understand more about the disease, learn how to live well despite the diagnosis, and research various treatment options.
“We are pleased to bring these much needed resources to the Spanish-speaking community living in the U.S.,” said Teva Neuroscience product manager, Mike Sheehy. “We believe it is important to provide Spanish-language materials and information that help people manage diseases, such as PD, to this important and growing community.”
Teva Neuroscience is headquartered in Kansas City, MO. For additional information about Teva’s Spanish resources for PD or AZILECT, visit http://azilect.com/espanol .
About AZILECT(R)(rasagiline tablets)
AZILECT is indicated for the treatment of the signs and symptoms of Parkinson’s disease both as initial therapy alone and to be added to levodopa later in the disease. The effectiveness of AZILECT was shown in patients with early PD who were receiving AZILECT as initial therapy alone and who were not receiving any other PD therapy. The effectiveness of AZILECT as adjunct therapy was shown in patients with PD who were treated with levodopa.
Important Safety Information:
— Patients should not take AZILECT if they are currently taking meperidine as it could possibly result in a serious reaction such as coma or death.
— Patients should not take AZILECT with tramadol, methadone, propoxyphene, dextromethorphan, St. John’s wort, mirtazapine, or cyclobenzaprine.
— Patients should not take AZILECT with other monoamine oxidase inhibitors (MAOIs), amphetamines, cold remedies containing decongestants and weight-reducing preparations containing pseudoephedrine, phenylephrine, phenylpropanolamine, or ephedrine in order to avoid a possibly dangerous increase in blood pressure. Symptoms of this reaction include severe headache, blurred vision, difficulty thinking, seizures, chest pain, unexplained nausea or vomiting, or signs or symptoms of a stroke. Patients or caregivers should seek immediate medical attention if these symptoms or other unusual symptoms occur.
— In order to prevent a possibly dangerous increase in blood pressure, patients taking AZILECT should avoid foods and beverages high in tyramine content such as aged cheeses, air-dried meats, pickled herring, yeast extract, aged red wines, tap/draft beers, sauerkraut, and soy sauce.
— Patients taking AZILECT should not have elective surgery requiring general anesthesia, and should not receive cocaine or other local anesthesia that contains ingredients that could raise blood pressure.
— Patients should inform their physician if they are taking, or planning to take, any prescription or over-the-counter drugs, especially antidepressants and ciprofloxacin.
— Patients with moderate to severe liver disease or a tumor of the adrenal gland should not take AZILECT.
— All PD patients are advised to monitor for melanoma (skin cancer) frequently and see a dermatologist on a regular basis.
— Side effects seen with AZILECT alone are headache, joint pain, and indigestion; and when taken with levodopa are uncontrolled movements (dyskinesias), accidental injury, nausea, weight loss, constipation, low blood pressure when standing, joint pain, vomiting, dry mouth, rash, and sleepiness. Patients should tell their doctor about these and any other side effects they experience when taking AZILECT.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch , or call 1-800-FDA-1088.
About Parkinson’s Disease
Parkinson’s disease is an age-related degenerative disorder of the brain. Symptoms can include tremor, stiffness, slowness of movement, and impaired balance. An estimated 1 million Americans have the disease, which usually affects people over the age of 60.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA), headquartered in Israel, is among the top 20 pharmaceutical companies in the world. The company develops, manufactures, and markets innovative and generic human pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva’s sales are in North America and Europe. Teva’s innovative R&D focuses on developing novel drugs for diseases of the central nervous system.
Teva’s U.S. innovative product marketing subsidiary, Teva Neuroscience, Inc., promotes AZILECT in the United States. AZILECT is a registered trademark of Teva Pharmaceutical Industries Ltd. Please visit http://www.AZILECT.com for additional important information.
Please see enclosed additional important information.